Iniparib is not abona fideinhibitor of poly(ADP-ribose) polymerase (PARP), so the clinical results in this context should not be extrapolated to other PARP inhibitors in developmentPreclinical data on iniparib did not sufficiently elucidate the mechanism of action of this agent before clinical ...
Additional trials are underway or awaiting final analysis with olaparib, other PARPis, and PARPi combinations to further elucidate the activity of these drugs in various clinical settings. This review will focus on the current clinical experience and ongoing trials with PARPis in ovarian cancer....
Hopkins:Until recently, large parts of the pharma industry resisted AI and machine learning, as these technologies were seen as disruptive to conventional ways of discovering and developing drugs. In fact, when Exscientia was founded more than a decade ago, we had to swim against the tide to m...
It is essential to distinguish between these pathways since there are different consequences to the surrounding cells in terms of inflammatory responses. Additionally, Kasof says that there are therapeutic drugs that target these pathways. As an example, he says that in cancer cells, apoptotic resis...
abbreviated approval processes, they are both versions of brand name drugs, and they share the same active ingredients as the brand name drugs. Both drugs are also useful because they “help to complete the cost of clinical trials and shorten the time that we can get these drugs to ma...
The simplest structure is blunt DSBs, and these are often referred to as “clean” breaks. These structures are preferred by c-NHEJ and will result in the rapid removal of these lesions, and therefore their toxicity is limited. Nonetheless, most chemotherapeutic drugs and radiotherapy as well ...
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Poly-ADP-ribose polymerase (PARP) inhibitors have Matulonis,Ursula,A.,... - 《Current Oncology Reports》 被引量: 8发表: 2016年 PARP inhibition in ovarian cancer: what is still missing? 1Ludwig Institute for Cancer Research, ...
In a phase III trial, the progression-free survival on regorafenib was 4.8 months.147 Thus, even with newer drugs such as regorafenib, resistance develops over time, suggesting that escape from ATP-competitive inhibitors of KIT and PDGFRA is inevitable. A new class of non-ATP mimetic kinase ...
the excitement about gynecologic cancers is really palpable for a number of reasons. There are some really exciting new drugs, including cellular therapeutics, immunotherapy,PARP(polyadenosinediphosphate-ribose polymerase) inhibitors, and ways of overcoming PARP resistance. Multiple new drugs as single age...
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 7, 76534–76550 (2016). PubMed PubMed Central Google Scholar Berns, K. & Berns, A. Awakening of “Schlafen11” to tackle chemotherapy resistance in SCLC. Cancer Cell 31, 169–171 (2017). ...